Skip to content
Study details
Enrolling now

Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

Southwest Autism Research & Resource Center
NCT IDNCT06526208ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

108

Study length

about 3 years

Ages

18–45

Locations

1 site in AZ

What this study is about

Researchers are testing whether a marijuana-based drug helps with anxiety in autistic adults. The trial is comparing the drug to a placebo (an inactive substance) to see if it reduces symptoms of anxiety. Participants will take the drug or placebo daily for 8 weeks, keeping a diary and attending clinic visits.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take MB-IMP

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Change in baseline on reported anxiety related symptoms

Body systems

Psychiatry / Mental Health